Skip to content
★ Sign in to follow
FB

Frontier Biotechnologies Inc. Stock: price and insider trades · China

前沿生物

CN·Mcap CN¥5.3BHealth Care

Frontier Biotechnologies Inc.: what insiders have been doing

Every trade that managers of Frontier Biotechnologies Inc. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. Between 22 October 2025 and 22 October 2026, 2 insiders published 11 filings.

All open-market trades in the period are sales: 11 sales worth €17.5M, by 2 insiders, with no purchase on record. One trade stands out by size: a sale of €4.4M from Rongjian Lu, disclosed on 11 August 2026.

Compared with its exchange (511 companies, median 2 filings), a count of 11 filings is above the norm. Since 2026, the database holds no purchases and 11 sales by insiders of the company.

Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. That lag is the time during which only the insider knows about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
11
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€17M
11 ops. · all time

Who traded when

BuySale
Rongjian Lu6 sales
Changjin Wang5 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 21,681 of 26,914 companies
30.2
score / 100
Value
22
Quality
38
FCF yld-5.2%
Earn yld-5.4%
EV/EBITDA·
ROE-2.1%
Gross mgn33%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥14.23
Analyst consensus
·
Income statement
RevenueCN¥123.4M
Gross profitCN¥41M33% margin
EBITDA-CN¥215.9M-175% margin
Net income-CN¥268.1M-5.8% margin
Valuation
PER (forward)-19.0x
P/Book5.2x
Beta0.87
Balance sheet & cash
Market capCN¥5.3B
Total debtCN¥408.9M
Free Cash Flow-CN¥256.5M
Debt / Equity41%
Profitability & ownership
ROE-2.1%
ROA-1.2%
% insiders41.5%
% institutions9.1%
Last declaration on 20 October 2026
Declarations11 total
  • ▼
    董事,高级管理人员,核心技术人员Executives
    10M CNY23SSE
    705,185 shares@ CN¥106.462514.8% of flowA股XSHGSSE:273000001745930700
  • ▼
    董事,高级管理人员,核心技术人员Executives
    10M CNY24SSE
    700,000 shares@ CN¥106.162915.7% of flowA股XSHGSSE:273000001745929820
  • ▼
    董事,高级管理人员,核心技术人员Executives
    9M CNY24SSE
    669,233 shares@ CN¥103.38617.3% of flowA股XSHGSSE:273000001739679230
  • ▼
    董事,高级管理人员,核心技术人员Executives
    8M CNY8SSE
    497,054 shares@ CN¥121.485413.4% of flowA股XSHGSSE:273000001609509150
  • ▼
    董事,高级管理人员,核心技术人员Executives
    3M CNY20SSE
    202,946 shares@ CN¥132.65326.6% of flowA股XSHGSSE:273000001466511840
  • ▼
    董事,高级管理人员,核心技术人员Executives
    14M CNY22SSE
    700,000 shares@ CN¥160.483631.5% of flowA股XSHGSSE:273000001187868670
  • ▼
    董事,高级管理人员,核心技术人员Executives
    34M CNY26SSE
    1,582,400 shares@ CN¥167.075365.0% of flowA股XSHGSSE:273000001187866460
  • ▼
    董事,高级管理人员,核心技术人员Executives
    2M CNY19SSE
    100,000 shares@ CN¥165.33334.1% of flowA股XSHGSSE:273000001164397600
  • ▼
    董事,高级管理人员,核心技术人员Executives
    22M CNY24SSE
    1,130,767 shares@ CN¥154.114149.4% of flowA股XSHGSSE:273000001141129440
  • ▼
    董事,高级管理人员,核心技术人员Executives
    13M CNY21SSE
    600,000 shares@ CN¥162.692424.3% of flowA股XSHGSSE:273000001141139800
  • ▼
    董事,高级管理人员,核心技术人员Executives
    9M CNY9SSE
    500,000 shares@ CN¥136.447519.1% of flowA股XSHGSSE:273000001118665180

11 of 11 declarations

About Frontier Biotechnologies Inc.

Qianyan Biotechnology is a company focused on the research and development of biotechnology, dedicated to the development and production of innovative drugs. The company is listed on the Chinese stock market with the ticker symbol XSHG.